ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
NCT07392723
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults with mild cognitive impairment and APOE4 genotype. By targeting the endogenous synthesis of docosahexaenoic acid (DHA) through ALA supplementation, the investigators aim to overcome the limitations of direct DHA supplementation, particularly in APOE4 carriers who exhibit low brain DHA levels and impaired blood-brain barrier function.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cognitive Dysfunction
- Alzheimer Disease
- Blood-Brain Barrier
- Apolipoprotein E, Deficiency or Defect of
- Brain Aging
- Fatty Acids, Omega-3
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Michal Schnaider Beeri, Ph.D.
- Last updated on ClinicalTrials.gov
- February 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 1
- Rutgers - Institute for Health · New Brunswick, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.